KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $5.2 million.

  • Arbutus Biopharma's Total Current Liabilities fell 7260.48% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 7260.48%. This contributed to the annual value of $15.6 million for FY2024, which is 3054.65% down from last year.
  • Per Arbutus Biopharma's latest filing, its Total Current Liabilities stood at $5.2 million for Q3 2025, which was down 7260.48% from $5.0 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Total Current Liabilities peaked at $32.9 million during Q4 2022, and registered a low of $5.0 million during Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's median Total Current Liabilities value was $20.3 million (recorded in 2024), while the average stood at $19.0 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 38422.23% in 2022, then tumbled by 7777.38% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Total Current Liabilities (Quarter) stood at $11.2 million in 2021, then skyrocketed by 192.82% to $32.9 million in 2022, then tumbled by 31.56% to $22.5 million in 2023, then plummeted by 30.55% to $15.6 million in 2024, then plummeted by 66.81% to $5.2 million in 2025.
  • Its Total Current Liabilities stands at $5.2 million for Q3 2025, versus $5.0 million for Q2 2025 and $19.4 million for Q1 2025.